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Abstract 17 
 18 
The intestinal disease coccidiosis, caused by protozoan parasites of the genus Eimeria, is 19 
one of the most important livestock diseases in the world.  It has a high impact in the poultry 20 
industry where parasite transmission is favoured by high-density housing of large numbers 21 
of susceptible birds.  Coccidiosis control in poultry is achieved by careful husbandry 22 
combined with in-feed anticoccidial drugs or vaccination with live parasites.  However, 23 
outbreaks of coccidiosis still occur and sub-clinical infections, which impact significantly on 24 
productivity and food security, are common due to widespread drug resistance, high parasite 25 
prevalence, and environmental persistence.  Herein, we review some recent approaches for 26 
the production of cheaper third generation vaccines, based on robust methods for 27 
identification of immunoprotective antigens and the use of transgenic Eimeria.  28 
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Sustainable poultry production in the face of Eimeria challenge 46 
Global poultry production has tripled in the last 20 years and the world’s chicken flock is 47 
estimated at approximately 21 billion, producing 1.1 trillion eggs and approximately 90 48 
million tonnes of meat (equivalent to ~ 60 billion carcasses) each year (www.faostat.fao.org).  49 
Expansion is predicted to continue for at least 30 years with Africa and Asia accounting for 50 
the most growth [1]. Commercial poultry production is possible only with the support of 51 
effective pathogen control, including good animal husbandry, chemoprophylaxis, and 52 
vaccination. A major and recurring problem is coccidiosis [2-4], an enteric disease caused by 53 
protozoan Eimeria species (see Glossary), which are parasitic coccidians with homoxenous 54 
faecal-oral life cycles (Figure 1) that are closely related to Toxoplasma, Neospora, and 55 
Isospora and more distantly related to other apicomplexans including Babesia, Plasmodium, 56 
and Theileria [5, 6]. Seven species of Eimeria infect the chicken with absolute host-57 
specificity, causing haemorrhagic (Eimeria brunetti, Eimeria necatrix, and Eimeria tenella) or 58 
malabsorptive (Eimeria acervulina, Eimeria maxima, Eimeria mitis, and Eimeria praecox) 59 
disease. These parasites are highly prevalent and can persist for long periods in the 60 
environment, including in faeces and litter (bedding/substrate).Thus, most chicken flocks in 61 
the world are exposed and many chickens become infected. Uncontrolled outbreaks cause 62 
high morbidity and mortality, and if infections are only partially controlled then sub-clinical 63 
disease is common and economically relevant because it causes poor feed conversion, 64 
reduced egg production, and failure to thrive. Comparison of the costs incurred by veterinary 65 
infectious diseases in the UK has highlighted coccidiosis as a leading problem in terms of 66 
total cost, including the cost of control [7]. The global economic impact of coccidiosis is 67 
unclear but has been estimated to be in excess of $3 billion USD per annum due to 68 
production losses combined with costs of prevention and treatment [8, 9]. Additional risk has 69 
been noted in much of the developing world where Eimeria can undermine the rapid 70 
expansion of poultry production and exert a profound impact on local poverty [10]. Costs in 71 
other livestock sectors where Eimeria parasites are also prevalent are less well defined but 72 
likely to be similarly high [11]. Links between eimerian infection and increased intestinal 73 
colonisation of bacterial pathogens such as Clostridium perfringens and Salmonella enterica 74 
serovars Typhimurium and Enteritidis increases risk to food security and raises concerns of 75 
zoonotic food-borne disease [12-14]. The global distribution of the Eimeria species, 76 
complemented by their ability for environmental survival as oocysts and their propensity for 77 
drug resistance, poses a serious threat to secure production of poultry-derived food 78 
products. The control of Eimeria remains as important now as it has ever been with the 79 
development of cost-effective, scalable vaccines required urgently.  80 
 81 
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Current options for control 82 
Successful commercialisation of poultry production in housed, free-range, and organic 83 
systems relies on effective control of Eimeria parasites. Good husbandry plays a key role in 84 
limiting oocyst sporulation and recycling through measures such as restricting bird access to 85 
faeces, maintaining litter quality, controlling house temperature, ventilation, and moisture 86 
levels, and thorough cleaning between flocks. However, husbandry alone is inadequate for 87 
control, and prophylactic anticoccidial drugs (ionophores and other chemicals) are crucial for 88 
sustainability of most production systems.  In the UK more than 40% of all antimicrobials 89 
sold for use in food and non-food animals are classified for the control of coccidial parasites 90 
(277 tonnes of active ingredient in 2011; mostly for control of Eimeria) with ionophores 91 
representing more than 70% of these [15].  Resistance to anticoccidial drugs has been 92 
recognized for decades and regarded as ubiquitous [16] with wide acceptance that drugs 93 
remain effective in the field only because they suppress parasite growth sufficiently to allow 94 
birds to develop natural immunity [17]. The speed at which resistance can appear, combined 95 
with legislative restrictions on the use of many in-feed drugs in some countries and 96 
consumer concerns regarding chemical residues in food products has discouraged most 97 
attempts to develop new anticoccidials.  98 
 99 
The major alternative option for coccidiosis control is vaccination, which is used effectively to 100 
protect egg-laying and breeder chickens but applied more rarely within the majority broiler 101 
sector. Anticoccidial vaccines are available in some countries for use with turkeys (for 102 
example Coccivac-T®), but vaccines targeting Eimeria species that parasitise mammals are 103 
yet to be commercialized. With one exception, all of the anticoccidial vaccines that are 104 
currently available are based on varied formulations of multiple live species of Eimeria. The 105 
development and compositions of these vaccines have been reviewed thoroughly in recent 106 
years and will not be described in depth here [3, 8, 18]. Briefly, live anticoccidial vaccines fall 107 
into two major groups. The first generation, based on formulations of live wild-type parasites, 108 
includes vaccines such as Coccivac®-B and -D and Immucox®, all of which are still currently 109 
available. First introduced in 1952, live wild-type vaccines rely on the controlled exposure of 110 
chickens to small numbers of virulent oocysts that initiate infection and induce a natural 111 
protective immune response. While  effective and still widely used in some sectors of the 112 
poultry production industry [3], these vaccines have a requirement for “even” vaccine 113 
distribution across the flock to avoid occurrence of disease. Ingestion of too-high a dose can 114 
cause a direct negative impact on feed conversion or even clinical symptoms of 115 
haemorrhagic or malabsorptive coccidiosis, while ingestion of too-small a dose leaves birds 116 
unprotected against large numbers of recycled vaccine oocysts excreted by other flock 117 
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members under anything but the very best flock management [19]. Recognition of the risk 118 
posed by vaccinal pathogenicity prompted development of second generation live 119 
attenuated vaccines. Most of these vaccines contain parasites derived by selection for the 120 
trait of “precocious” development (i.e., more rapid completion of the life cycle with a reduced 121 
pre-patent period, lower reproductive capacity and consequential reduction in pathogenicity). 122 
Parasite lines selected through multiple rounds of in vivo passage to be capable of 123 
completing their life cycles 13-33 hours faster than their wild-type progenitor retain full 124 
immunoprotective capacity while losing one, or even two, rounds of schizogony [20, 21], 125 
making them safer, and attenuated vaccines. A small number of attenuated lines have also 126 
been developed by serial passage of parasites through embryonating eggs [21-23], a 127 
process that results in parasites that are significantly less pathogenic for chickens than their 128 
wild-type progenitor [24]. Second generation vaccines were introduced nearly 40 years after 129 
the first wild-type vaccines and include Paracox® (attenuated by selection for precocity, 130 
registered 1989) and Livacox® (attenuated by selection for precocity or egg adaptation, 131 
registered 1992), which remain highly successful with > 1 billion doses of the former sold 132 
each year [25]. The marketing of these major second generation products has in turn 133 
stimulated the generation of several more attenuated lines from parasites around the world 134 
as the basis of regional vaccines (e.g., [26-28]). These successes have been tempered, 135 
however, by inherent production limitations. Eimeria parasites cannot yet be propagated 136 
efficiently in vitro [29, 30], which means all vaccine lines have to be grown in chickens. The 137 
relatively low reproductive index of attenuated compared to wild-type vaccine lines increases 138 
production, and thus retail, costs (retail between UK £0.04 and £0.30 per dose depending on 139 
formulation; http://www.animal-meds.co.uk/), and perhaps more importantly imposes 140 
practical limitations on the number of doses that can be produced. For these reasons, live-141 
attenuated vaccine usage is confined mainly to the breeding and egg-laying sectors of the 142 
poultry industry. Attempts to develop live vaccines attractive to the broiler sector, where 143 
economic margin per bird is much lower, have included simplified formulations containing 144 
fewer parasite species such as Coccivac®-B, Paracox®-5, and Livacox® T, but uptake 145 
remains low with only about 5-10% of the poultry produced each year receiving an 146 
anticoccidial vaccine. To make a significant impact a third generation of cheaper, and more 147 
readily up scalable, anticoccidial vaccines is required. 148 
 149 
What has happened to the third generation anticoccidial vaccines? 150 
Throughout the 1980s and 1990s, numerous efforts were made to identify parasite antigens 151 
and the genes that encode them as novel targets in the development of third generation 152 
subunit anticoccidial vaccines (reviewed extensively in [3]). Unfortunately progress has been 153 
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extremely limited to date, reflecting the general difficulty experienced in the identification of 154 
antiprotozoal or antiparasite vaccine candidates and the limitations of testing for 155 
immunogenicity, rather than ability to induce immune protection [31]. The likely requirement 156 
for more than one antigen if subunit vaccination is to become a viable alternative to 157 
chemotherapy has added further complication. Commercial problems including the cost of 158 
developing and licensing new vaccines, protecting intellectual property and the risk of 159 
resistance developing to any vaccine based on a small number of immunoprotective 160 
antigens served to further dampen enthusiasm within the industry. To date only CoxAbic®, a 161 
subunit vaccine prepared from E. maxima affinity purified gametocyte antigens (APGA), has 162 
been successfully commercialized [32, 33]. While CoxAbic® has been reported to be 163 
effective in the field [32, 34], in common with the live anticoccidial vaccines it relies on 164 
parasite propagation in chickens for its production and remains limited by production 165 
capacity and relative expense, further complicated by the need for antigen purification [30].  166 
 167 
Vaccine development strategies have included the testing of recombinant protein, DNA, 168 
dendritic cell-derived exosome, and vectored subunit vaccines (Table 1), all relying on the 169 
identification of one or more appropriate antigens. Early studies focused on antigens 170 
identified on the basis of host immune recognition, and led to the identification of several 171 
proteins involved in host-parasite interaction and invasion. Microneme proteins 1 (also 172 
identified as Etp100 and TFP100), 2 and 4 (TFP250) were tested as recombinant proteins 173 
[35-37]; more recently a rhomboid-like protease linked to invasion has received attention 174 
[38], and GPI-linked surface antigens including EtSAG1 (also identified as TA4) have been 175 
re-visited and widely tested with mixed results [39-41]. Other immunogenic parasite 176 
molecules such as α-tubulin have been tested as recombinant protein [42]. A putative 177 
fibronectin was investigated using monoclonal antibodies [43] and various proteins from the 178 
sporozoite refractile bodies including SO7 (also identified as RB1 and GX3262), refractile 179 
body protein 1A, and lactate dehydrogenase have been tested using multiple approaches 180 
[40, 44-47]. Profilin (also identified as 3-1E) has been tested more than any other eimerian 181 
antigen as both an anticoccidial vaccine candidate and an adjuvant [48-54]. Attempts have 182 
also been made to define the immunoprotective component of the APGA CoxAbic® vaccine 183 
through investigations into gametocyte antigens gam56 and gam82 [55-57]. Unfortunately, 184 
while partially protective effects have been reported in many of these experimental challenge 185 
studies, progress towards vaccine commercialization has not followed for any of them. 186 
Efforts to improve efficacy and reproducibility have included production of hybrid proteins, 187 
DNA, and synthetic vaccines [40, 58, 59], testing of novel adjuvants including a range of 188 
Montanide oil-based adjuvants, ginsenosides and plant saponins [36, 53, 60], and co-189 
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administration  of avian cytokines including interleukin (IL)-1β, IL-2, IL-8, IL-15, interferon 190 
(IFN)α, IFNγ, transforming growth factor (TGF)-β4, and lymphotactin [49]. The reasons why 191 
none of these approaches have reached field-testing or commercialization remain obscure 192 
but clearly indicate lack of reproducible, efficacious vaccine protection. This could be due to 193 
inherent insufficiencies in the immunoprotective capacities of the tested antigens or reflect 194 
limitations in the vaccine delivery strategies used. Many parasite antigens exposed to the 195 
host during in vivo replication are highly immunogenic, but the majority of these do not 196 
induce immune responses that block re-infection. Ultimately it is highly likely that more than 197 
a single antigen will be needed to induce solid immune protection against each Eimeria 198 
species, suggesting that co-vaccination with multiple existing or new vaccine candidates 199 
should be tested as part of future vaccine development programmes.  200 
 201 
New approaches 202 
Recent changes to legislation governing the use of anticoccidials in many countries such as 203 
those within the EU and a general expansion of interest in food security issues have 204 
stimulated renewed interest in the development of third generation anticoccidial vaccines. 205 
Given the paramount importance of identifying effective vaccine candidates, attention has 206 
focused on robust strategies for their identification. Improved understanding of molecules 207 
that are essential to host-parasite interaction can highlight new candidates. For example, the 208 
use of cell-based and carbohydrate microarray assays to investigate the role played by E. 209 
tenella microneme protein 3 (EtMIC3) in site-specific invasion of the chicken intestine 210 
suggested that vaccines based on the microneme adhesive repeat regions (MARR) from this 211 
protein may be effective at blocking invasion [61]. Testing single, multiple, and/or hybrid 212 
MARR as recombinant protein and DNA vaccines demonstrated significant immune 213 
protection against E. tenella infection in a series of small-scale challenge studies [61].  214 
 215 
Transcriptome-wide screening approaches have been used recently to identify novel vaccine 216 
candidates both in vivo and in silico. Zhu and colleagues used the eukaryotic expression 217 
vector pVAX1.0 to create and test an E. acervulina sporozoite expression library [62]. 218 
Sequential rounds of screening by vaccination identified two candidate cDNA clones (cSZ-219 
JN1 and cSZ-JN2), each of which, when tested individually, induced immune protection in 220 
terms of weight gain, lesion score, and oocyst output [62, 63]. While useful in this example 221 
the potential for confounding factors should be noted including the risk of combining antigens 222 
which induce antagonistic and protective immune responses in the same pool, as described 223 
for Leishmania donovani [64], as well as the need to choose an immunologically relevant life 224 
cycle stage. In silico approaches to the same problem rely on access to good quality 225 
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datasets. Klotz and colleagues generated a cDNA library from E. tenella sporozoites and 226 
sequenced 191 clones [65]. Working on the hypothesis that many parasite proteins expected 227 
to interact with the host immune system are likely to be secreted, all open reading frames 228 
predicted to encode a signal peptide sequence were examined, and six were tested for 229 
vaccinal potential, highlighting two surface antigen (EtSAG)-like sequences and a putative 230 
Plasmodium falciparum Pfs40 homologue [65]. The recent expansion in genomic and 231 
transcriptomic resources for Eimeria species (Reid et al., unpublished) (see 232 
http://www.genedb.org/Homepage/Etenella) now finally provides resources appropriate for 233 
larger, more systematic transcriptome-wide in silico analyses.  234 
 235 
Recognizing the importance of immune protection, rather than immune stimulation, also 236 
prompted the creation of genome-wide genetic mapping studies to identify vaccine 237 
candidates. Building on previous observations that strain-specific immune selection of 238 
genetically distinct E. maxima strains conferred a highly selectable phenotype [66], genomic 239 
regions whose inheritance conferred susceptibility to immune selection were mapped using 240 
a ‘hitch-hiker’ mapping strategy (Figure 2) [67]. Differences in the inheritance of strain-241 
specific genetic markers by progeny of multiple crosses between antigenically distinct E. 242 
maxima strains, with or without strain-specific immune selection, identified six genomic 243 
regions likely to encode immunoprotective antigens. Detailed fine mapping of two of these 244 
regions has identified apical membrane antigen-1 (EmAMA-1) and immune mapped protein-245 
1 (EmIMP-1) as vaccine candidate antigens. In vivo testing of these two candidates using 246 
DNA and recombinant protein vaccination has confirmed their annotation as valid 247 
anticoccidial vaccine candidates. Amongst the strengths of the genetic mapping approach is 248 
the removal of confounding factors such as antigenic dominance, stage-specific protein 249 
expression, or site of protein localization, and the fact that immune killing is used as an 250 
absolute readout of immunoprotective antigenicity. Again, availability of genomic resources 251 
for Eimeria species combined with next-generation sequencing technologies promotes 252 
extension of genetics-led strategies for vaccine development and improved understanding of 253 
other selectable traits.  254 
 255 
Beyond the identification of effective vaccine candidates, the context and environment in 256 
which antigens are delivered to hosts are of fundamental importance. DNA and recombinant 257 
protein vaccinations have become valuable tools, but the current labour-intensive routes of 258 
application suggest that they are unlikely to be accepted as mainstream commercial 259 
vaccines for the mass poultry markets. The scale and tight economic margins of poultry 260 
production indicate a requirement for low input, easily administered vaccines. For third 261 
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generation anticoccidial vaccines a number of vectored approaches have been tested with 262 
many of the antigens described above.  Fowlpox virus (FWPV) and herpes virus of turkeys 263 
(HVT) are effective vectors for delivery of E. acervulina refractile body transhydrogenase and 264 
lactate dehydrogenase under experimental conditions [46]. Both of these viruses are 265 
licensed for use in poultry, and a small number of recombinant FWPV and HVT vaccines are 266 
commercially available, offering protection against diseases including Newcastle disease, 267 
infectious bursal disease, and infectious laryngotracheitis. Several bacterial vectors have 268 
also been tested with Eimeria antigens under experimental conditions including Escherichia 269 
coli [68], Salmonella Typhimurium [69-72], and Mycobacterium bovis [73], all of which offer 270 
plausible commercial possibilities.  Also offering commercial potential are plant vector 271 
systems, in which vaccination can theoretically be incorporated into routine dietary 272 
components. Preliminary trials in which the microneme proteins EtMIC1 and EtMIC2 have 273 
been expressed in the tobacco plant Nicotiana tabacum have yielded promising results [74, 274 
75]. In other trials expression of single chain variable fragment (scFv) antibodies with affinity 275 
for EtSAG1 expressed in seeds of the fodder pea (‘Eiffel’ variety) reduced E. tenella 276 
replication in birds following forced feeding [76].  277 
 278 
Standardising vaccine assessment and development 279 
Over the last 30 years many antigens have been tested as novel anticoccidial vaccine 280 
candidates, generating a vast amount of new data on different aspects of parasite biology 281 
and identifying potential targets for intervention. Unfortunately lack of standardisation 282 
between experiments, research groups, government agencies, and industry has hampered 283 
meaningful comparisons. Experimental variables such as the breed/line of chicken and 284 
parasite species/strain used [66, 77] as well as considerations including the choice of DNA 285 
vaccine vector or recombinant protein expression system, the type of buffer or adjuvant, the 286 
dose, frequency and site of immunization, and the specific methods used to measure 287 
vaccine efficacy, all exert profound influences on experimental outcomes. Variation in diet 288 
has also been shown to significantly influence the results of anticoccidial vaccination using a 289 
recombinant protein where phytonutrient concentration affected the type and magnitude of 290 
immune response during challenge as well as weight gain and parasite replication [78]. 291 
While phytotherapy and pre-/probiotics are yet to become established as convincing 292 
anticoccidial strategies [79], it is clear that environmental variation has an impact on 293 
eimerian replication and is highly likely to influence responses to vaccination. While this 294 
problem is not specific to research with Eimeria, the establishment of harmonised guidelines 295 
for the testing of anticoccidial subunit vaccine candidates, drugs and diagnostics, as has 296 
already been described for live vaccines [80], would support best practice and community 297 
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recognition of the most effective antigens, and could provide a relevant scale of efficacy for 298 
new contenders. Ultimately any third generation anticoccidial vaccine will require rigorous 299 
testing comparable to that specified by the British and European Pharmacopoeia for live 300 
coccidiosis vaccines [81] before it can be registered. 301 
 302 
New opportunities 303 
Broader biological work that has been ongoing with Eimeria parasites is now providing 304 
opportunities for improved control of coccidiosis.  Protocols supporting genetic 305 
complementation and modification by transgenesis are immensely powerful tools for cell 306 
biological and genetics studies in several genera of apicomplexan parasites. Recent 307 
progress in this field with Eimeria allows creation of transgenic parasite lines expressing one 308 
or more foreign proteins [82, 83], prompting the notion that Eimeria species could be used as 309 
host-specific vaccine delivery vectors. Preliminary tests indicated that E. tenella is capable of 310 
expressing enhanced yellow fluorescent protein (EYFP) as a model antigen that stimulates a 311 
range of humoral and cell-mediated immune responses in the chicken following oral 312 
vaccination with genetically modified oocysts [84]. More recently, experimental oral 313 
vaccination of chickens with E. tenella parasites expressing Campylobacter jejuni antigen A 314 
(CjaA) was found to stimulate an anti-C. jejuni immune response and reduce C. jejuni 315 
colonization of the gut by between 86% and 91% compared to controls [85]. Successful 316 
genetic complementation of other Eimeria species including E. acervulina, E. maxima, and 317 
E. praecox, as well as the rat-specific Eimeria nieschulzi [29, 67, 86], support the potential 318 
use of these less pathogenic species and strains as vectors to develop novel types of 319 
anticoccidial vaccines that may induce immunoprotection against other veterinary or 320 
zoonotic pathogens such as C. jejuni or avian influenza [87]. 321 
 322 
Changing focus to the host, a number of independent genetics studies have compared and 323 
quantified Eimeria replication in genetically distinct lines of inbred and outbred chicken, 324 
revealing between two- and fourfold variations in overall susceptibility to different parasite 325 
species [77, 88]. Recent availability of detailed genomic resources for the chicken, including 326 
a full draft genome sequence and high-density single nucleotide polymorphism (SNP) arrays 327 
[89] now permit the detailed genetic mapping, sequencing, and testing of loci and genes 328 
associated with resistance phenotypes. 329 
 330 
Concluding remarks 331 
Coccidiosis caused by parasitic Eimeria species remains one of the greatest burdens on the 332 
economics of production of poultry and poultry-derived products. While control is widely 333 
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available through the use of anticoccidial drugs, and live first and second-generation 334 
vaccines, neither of these are completely satisfactory, and new strategies are urgently 335 
required. A third generation of more cost-effective anticoccidial vaccines seems to be 336 
feasible with several candidate antigens described and many reports of partial protection in 337 
experimental settings. However, none of these approaches has progressed into commercial 338 
development despite more than 25 years of research [90, 91].  Comparison with progress for 339 
other apicomplexans, including high profile human pathogens such as P. falciparum, make it 340 
clear that whilst vaccines are far from straightforward, they are at least technically possible 341 
[92]. Despite many apparently promising candidates falling by the wayside there is now a 342 
small panel of realistic vaccine contenders. Future challenges will include identification of 343 
optimal delivery strategies and how we respond to parasite evolution in the face of vaccine 344 
selection.  Of great importance, the genomes of all seven Eimeria species that infect the 345 
chicken are now sequenced and undergoing analysis and annotation (Reid et al., 346 
unpublished) (see http://www.genedb.org/Homepage/Etenella). Such resources will be 347 
invaluable in the discovery of novel targets for anticoccidial vaccine or drug intervention and 348 
identification of putative homologues in each species.  349 
 350 
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Figure legends 562 
Figure 1. A generalised life cycle for parasites within the Eimeria genus. 563 
1. Ingestion of a sporulated oocyst initiates the endogenous phases of the Eimeria life cycle. 564 
2. For avian Eimeria species the tough oocyst wall is disrupted mechanically during passage 565 
through the crop or gizzard, releasing four sporocysts from each sporulated oocyst. For 566 
Eimeria which infect mammals, enzymatic digestion is likely to be more important as the 567 
oocyst traverses the stomach and proximal intestine. 3. Exposure to digestive enzymes 568 
allows the sporozoite to escape the sporocyst as it passes through the intestine. The 569 
sporozoite continues to pass through the intestinal lumen until it attaches to and invades the 570 
epithelial layer. The exact site of invasion varies for each Eimeria species [2, 3]. 4. Inside the 571 
epithelial cell the sporozoite rounds up into a trophozoite before undergoing schizogony 572 
(asexual multiple fission), resulting in the production of multiple first generation merozoites 573 
which rupture and leave the host cell. 5. Each first generation merozoite invades another 574 
epithelial cell prior to entering a second round of schizogony, leading to production of second 575 
generation merozoites. One, two or more rounds of schizogony may follow. 6. After a 576 
parasite species-specific finite number of schizogonies the final generation of merozoites 577 
differentiate into gametes as the sexual phase of the life cycle begins, forming 578 
macrogametocytes, which develop into uninucleate macrogametes (♀), or 579 
microgametocytes which produce large numbers of motile, biflagellated microgametes by 580 
multiple fisson (♂). 7. Mature microgametes leave the host cell and penetrate neighbouring 581 
cells, fertilising mature macrogametes to form zygotes. 8. After fertilisation the macrogamete 582 
forms a resistant wall as it transforms into an oocyst which escapes from the host cell into 583 
the intestinal lumen to be excreted into the environment to initiate the exogenous phase. 9. 584 
The unsporulated (non-infectious) oocyst undergoes sporulation in the environment requiring 585 
warmth, oxygen and moisture as it undergoes sequential meiotic and mitotic nuclear division 586 
to become a sporulated oocyst. The sporulated oocyst, which contains four sporocysts, each 587 
of which contain two sporozoites, is now infectious. 588 
 Each stage of the Eimeria life cycle within the host is known to be immunogenic, with 589 
the early life cycle stages considered to be most important in the induction of a protective 590 
immune response [33, 93, 94]. Few of the current anticoccidial vaccine candidates are 591 
expressed throughout the Eimeria life cycle and it is likely that multiple antigens will be 592 
required if an effective subunit vaccine is to be established. 593 
 594 
 595 
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Figure 2. Genetic mapping of loci encoding essential immunoprotective antigens as novel 596 
vaccine candidates [67]. (a) Antigenically distinct Eimeria maxima red and blue strains 597 
genotyped at a panel of marker loci (twelve used in this example), two of which are absent 598 
from the red strain, three absent from the blue strain. Marker red-6 (highlighted in black) is 599 
closely linked to a gene that encodes a strain-specific immunoprotective antigen. (b) In the 600 
absence of immune selection each hybrid progeny population will contain every marker, 601 
which defines either parent within a pool of multiple, genetically heterogeneous clones 602 
arising from meiotic segregation and recombination. (c) Under red strain-specific immune 603 
selection all progeny parasites expressing the red strain-specific antigen will be killed, 604 
removing or severely reducing the occurrence of genetically linked marker red-6. Thus, 605 
genes closely associated with marker 6 within the red strain genome will be assessed for 606 
vaccine candidacy. 607 
 608 
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Box 1. Outstanding questions 610 
 Which of the 8,000-9,000 antigens encoded within each eimerian genome is capable of 611 
stimulating a protective immune response? 612 
A small number of defined subunit vaccine candidates have been identified, but none 613 
have reached clinical development. 614 
 If antigens appropriate for use as defined subunit vaccines are identified, how can they 615 
be delivered to poultry in a cost effective manner? 616 
 How can immunisation be optimised in young, immunologically naive chickens? 617 
The identification of optimal delivery mechanisms and adjuvants will be crucial. 618 
 To what extent are Eimeria capable of evolving to avoid subunit vaccine-induced 619 
immune killing, and how can we minimise this risk? 620 
 621 
  622 
19 
 
Tables 623 
 624 
Table 1. Summary of the most widely tested anticoccidial subunit vaccine candidates. 625 
 
Form of delivery tested 
Vaccine candidate Proteina DNAb Vectoredc 
Apical membrane antigen-1  [67]  [67]  [67] 
gam56  [57]  [58] n/d 
gam82  [56] n/d n/d 
Microneme protein 2  [95]  [96]  [75] 
Microneme protein 3  [61]  [61] n/d 
Immune mapped protein-1  [67]  [67]  [67] 
Lactate dehydrogenase  [47]  [97]  [46] 
Profilin (3-1E)  [78]  [49] n/d 
Rhomboid-like proteins  [98]  [98]  [73] 
SO7  [99]  [65]  [69] 
TA4  [39]  [58]  [72] 
 626 
aProtein vaccination: antigen expressed as a recombinant protein (e.g. bacterial expression) 627 
prior to vaccination, usually delivered by subcutaneous or other site injection supplemented 628 
with an adjuvant such as Freund’s Incomplete Adjuvant. 629 
bDNA vaccination: complete or partial antigen sequence presented within a eukaryotic 630 
expression vector under control of a strong promoter designed to drive transcription and 631 
translation of the vaccine antigen in vivo, usually delivered by intra-muscular or other site 632 
injection. 633 
cVectored vaccination: use of genetically modified virus, bacteria, parasite, yeast or plant to 634 
express a vaccinal antigen and deliver it to the vaccinated animal either in a live or killed 635 
formulation. 636 
Abbreviations: , tested and found to be effective; n/d, not determined. 637 
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 639 
Glossary 640 
Anticoccidial chemicals: anticoccidial drugs produced by synthesis, distinct from the 641 
ionophores. Examples include decoquinate, diclazuril and robeindine. 642 
Antigenic dominance: immunogenic antigens that stimulate a strong immune response and 643 
overwhelm other, potentially immunoprotective, antigens. In this example screening immune 644 
responses of convalescent animals can reveal the dominant immunogenic, but not 645 
necessarily immunoprotective, antigens providing potentially false leads in subunit vaccine 646 
development. 647 
Attenuated anticoccidial vaccine: live vaccines containing one or more Eimeria species 648 
parasites attenuated by selection for precocious development or serial passage in 649 
embryonated eggs. Attenuation results in reduced reproductive capacity and consequentially 650 
a reduced risk of clinical or sub-clinical disease. 651 
Eimeria: genus of apicomplexan parasite. Seven species are recognized to infect the 652 
chicken. 653 
Gametocyte: the sexual stages of the Eimeria life cycle. 654 
Haemorrhagic coccidiosis: disease caused by Eimeria brunetti, Eimeria necatrix and Eimeria 655 
tenella, characterized by haemorrhagic enteritis. 656 
Hitch-hiker genetic mapping: population-based genetic mapping strategy to identify genes 657 
which associate with a selectable phenotype through detection of changes in the occurrence 658 
of polymorphic, but potentially neutral, genetic markers that are physically linked to a 659 
causative locus. 660 
Homoxenous faecal-oral life cycle: Single host parasite life cycle, transmitted by ingestion of 661 
faecally contaminated environmental material (e.g. food, water, bedding, preening).  662 
Ionophores: lipid soluble antimicrobials produced by fermentation. The major drug class 663 
used to control Eimeria. Examples include monensin, narasin and salinomycin. 664 
Malabsorptive coccidiosis: disease caused by Eimeria acervulina, Eimeria maxima, Eimeria 665 
mitis and Eimeria praecox, characterized by mucoid enteritis. 666 
Poultry production systems: 667 
 Breeder: chicken produced to breed future generations of broiler, layer or other 668 
chickens. 669 
 Broiler: chicken produced for meat production. 670 
21 
 
 Free-range: chickens produced for meat and/or eggs that are allowed freedom to 671 
roam for food, usually within an enclosed area but with provision for extensive 672 
movement in the open air. 673 
 Housed: chickens produced for meat and/or eggs enclosed within a building 674 
(‘house’). House design varies between regions, usually featuring two or more wire 675 
walls in tropical and hot regions but enclosed within solid walls in more temperate 676 
and colder regions. 677 
 Layer: chicken produced and maintained for egg production.  678 
 Organic: chicken production for meat and/or eggs in any form of accommodation 679 
achieved without the use of synthetic products, including drugs or growth promoters 680 
for the chickens or their food, or genetic modification. 681 
Phytotherapy: The use of extracts from natural sources such as plants as medicinal or 682 
health-promoting products. 683 
Oocyst: a cyst formed by a protozoan parasite. For Eimeria this is the environmentally-684 
resistant stage of the life cycle and the infectious unit. 685 
Schizogony: asexual reproduction by multiple fission. 686 
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